President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

a JAK inhibitor it sells as Jakafi to treat various haematological cancers and in a topical form as Opzelura for atopic dermatitis and vitiligo. Deuruxolitinib is a deuterated form of ruxolitinib ...

A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis ...

William Truswell, MD, FACS, operates his own cosmetic and reconstructive facial surgery practice. Dr. Truswell was the first in his area in Western Massachusetts to have an accredited private ...

Barbara Obstoj-Cardwell is the Managing Editor of The Pharma Letter, which in 2010 acquired the archives of The Pharma Marketletter, a publication that Barbara owned since 1991 and prior to that ...